Fasting Bioequivalence Study of 2 Oral Progesterone Soft Capsules 200 mg in 48 Healthy Female Subjects
Status:
Completed
Trial end date:
2020-01-07
Target enrollment:
Participant gender:
Summary
This study was designed to assess the bioequivalence of single oral dose of Progesterone 200
mg Soft Capsule (JSC "Farmak", Ukraine) Versus Utrogestan® 200 mg Soft Capsule (Manufacturer
by: Cyndea Pharma, S.L., Spain, MAH: Laboratoires Besins International, France) In healthy
female subjects under fasting conditions